U.S. Markets open in 4 hrs 12 mins
  • S&P Futures

    4,533.25
    -42.50 (-0.93%)
     
  • Dow Futures

    34,559.00
    -63.00 (-0.18%)
     
  • Nasdaq Futures

    15,687.50
    -301.00 (-1.88%)
     
  • Russell 2000 Futures

    2,156.20
    -49.00 (-2.22%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    51,212.03
    +3,366.96 (+7.04%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Altria Reports 2021 Third-Quarter and Nine-Months Results; Announces Expanded Share Repurchase Program; Narrows 2021 Full-Year Earnings Guidance

  • Oops!
    Something went wrong.
    Please try again later.
·26 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RICHMOND, Va., October 28, 2021--(BUSINESS WIRE)--Altria Group, Inc. (Altria) (NYSE: MO) today reports its 2021 third-quarter and nine-months business results, announces the expansion of its existing share repurchase program and narrows its 2021 full-year adjusted diluted earnings per share (EPS) guidance.

"Altria continued to balance maximizing profitability from our core tobacco businesses with investing to realize our Vision of responsibly leading the transition of adult smokers to a smoke-free future," said Billy Gifford, Altria’s Chief Executive Officer. "Our tobacco businesses performed well against difficult year-over-year comparisons and we’re encouraged by the significant retail share growth from on! in the third quarter. We also continued to reward shareholders with a strong and growing dividend and announced today the expansion of our existing $2.0 billion share repurchase program to $3.5 billion."

"We are raising the lower-end of our full-year 2021 guidance and now expect to deliver adjusted diluted EPS in a range of $4.58 to $4.62. This range represents a growth rate of 5% to 6% from a $4.36 base in 2020."

Altria Headline Financials1

($ in millions, except per share data)

Q3 2021

Change vs.

Q3 2020

Q3 YTD 2021

Change vs.

Q3 YTD 2020

Net revenues

$6,786

(4.7)%

$19,758

(0.5)%

Revenues net of excise taxes

$5,531

(2.6)%

$16,025

1.5%

Reported tax rate

17.6%

100.0+ pp

44.9%

3.1 pp

Adjusted tax rate

24.9%

(0.9) pp

24.9%

0.2 pp

Reported diluted EPS2

$(1.48)

(100)%+

$0.46

(66.2)%

Adjusted diluted EPS2

$1.22

2.5%

$3.52

4.5%

1 "Adjusted" financial measures presented in this release exclude the impact of special items. See "Basis of Presentation" for more information.

2 "EPS" represents diluted earnings (losses) per share attributable to Altria.

As previously announced, a conference call with the investment community and news media will be webcast on October 28, 2021 at 9:00 a.m. Eastern Time. Access to the webcast is available at www.altria.com/webcasts.

Cash Returns to Shareholders and Capital Markets Activity

Share Repurchase Program

  • Yesterday, Altria’s Board of Directors (Board) authorized the expansion of Altria’s existing $2 billion share repurchase program to $3.5 billion. Altria expects to complete the expanded program by December 31, 2022. Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of Altria’s Board.

  • Through September 30, 2021, Altria repurchased:

    • 6.7 million shares at an average price of $48.35, for a total cost of $322 million in the third quarter.

    • 20.2 million shares at an average price of $48.17, for a total cost of $972 million in the first nine months.

  • Following the expansion of the share repurchase program, Altria has approximately $2.5 billion remaining in the $3.5 billion share repurchase program.

Dividends

  • In the third quarter, Altria paid $1.6 billion in dividends.

  • In August, Altria’s Board increased Altria’s regular quarterly dividend for the 56th time in the past 52 years. Altria’s current annualized dividend rate is $3.60 per share, representing a dividend yield of 7.5% as of October 25, 2021.

  • Altria maintains its long-term objective of a dividend payout ratio target of approximately 80% of its adjusted diluted EPS. Future dividend payments remain subject to the discretion of Altria’s Board.

Ste. Michelle Wine Estates Transaction

On October 1, 2021, UST LLC completed the sale of its Ste. Michelle Wine Estates business and received net cash proceeds of approximately $1.2 billion, which Altria used to partially fund its expanded share repurchase program. In the third quarter, Altria recorded a pre-tax charge of $51 million related to the disposition.

Smoke-free Products Business Platform

Heated Tobacco

  • In the third quarter:

    • Marlboro HeatSticks retail sales volume increased by over 20% sequentially, primarily driven by broader distribution outside of established metro markets and increasing demand in the Northern Virginia metro market.

    • Marlboro HeatSticks achieved a cigarette category retail share of 1.8% in Northern Virginia stores with distribution for the last four weeks of the third quarter.

  • In September 2021, in the IQOS heated tobacco system patent proceedings, the International Trade Commission (ITC) imposed an importation ban and issued cease-and-desist orders (CDO) on IQOS, Marlboro HeatSticks and infringing components. Altria disagrees with the ITC’s decision as it believes that the plaintiff’s patents are invalid and that IQOS does not infringe those patents. The ITC’s decision is currently under a 60-day review by the Biden Administration. If the decision is not rejected through the Administration’s review, the CDO will take effect on November 29, 2021, making all IQOS and Marlboro HeatSticks products unavailable in the marketplace. PM USA is preparing to comply with the orders. PM USA is also preparing contingency plans surrounding sales and distribution, and has been in communication with Philip Morris International Inc. regarding their domestic manufacturing plans.

Oral Tobacco

  • Total U.S. oral tobacco category share for on! nicotine pouches grew to 3.0% in the third quarter, an increase of 1.0 percentage point sequentially and an increase of 1.9 percentage points from the end of 2020.

  • As of September 30, 2021, Helix had broadened the U.S. distribution of on! to over 110,000 stores.

  • Premarket tobacco product applications (PMTA) for the entire on! portfolio remain pending with the U.S. Food and Drug Administration (FDA). Helix is actively working on modified risk tobacco product applications for on!.

  • In October 2021, the FDA authorized the marketing of Verve Discs and Verve Chews in the flavors of Green Mint and Blue Mint and determined that the marketing of these products is appropriate for the protection of public health. This is the first flavored product authorization issued by the FDA for newly deemed tobacco products. While Verve products are not currently in market, Altria believes it gained learnings from developing the Verve PMTA submission that it used to file its May 2020 PMTA submissions for on!, nine months after Altria closed the on! transaction.

ABI Investment

Impact of COVID-19 Pandemic and Pre-Tax Impairment Charge

  • The fair value of Altria’s investment in ABI has been below its carrying value since October 2019 and has not fully recovered. At September 30, 2021, the fair value of Altria’s investment in ABI was below its carrying value by 35%.

  • ABI continued to be impacted by the COVID-19 pandemic, including the effects of COVID-19 variants, supply-chain constraints across certain markets, transactional foreign exchange and commodity cost headwinds.

  • In preparing Altria’s financial statements for the period ended September 30, 2021, Altria considered the factors discussed above and Altria’s expectation for ABI’s recovery. While Altria continues to believe that ABI’s share price will recover, Altria concluded that a full recovery to its carrying value will take longer than previously expected.

  • As a result of Altria’s evaluation and in accordance with applicable accounting guidance, Altria determined that the decline in fair value of its investment in ABI as of September 30, 2021 was "other than temporary." Therefore, Altria recorded a non-cash pre-tax impairment charge of approximately $6.2 billion for the three and nine months ended September 30, 2021, reflecting the difference between the fair value of Altria’s investment in ABI using ABI’s share price at September 30, 2021 and the carrying value of Altria’s investment in ABI at September 30, 2021.

Strategic Review of ABI Investment

The five-year transfer restriction of the 185 million ABI shares that Altria received in the 2016 ABI and SABMiller plc business combination expired on October 10, 2021.

Altria views its ABI stake as a financial investment and is focused on maximizing the long-term shareholder value of the investment. In anticipation of the expiration of the lock-up, Altria conducted an in-depth analysis of its investment in ABI considering a range of factors, including: (i) the strategic rationale for continuing as a long-term investor in the beer category; (ii) ABI’s share price (which has declined by more than 30% since October 2019 due in large part to the effects of the COVID-19 pandemic on its business); (iii) expectations for ABI’s business; (iv) alternative uses of capital; and (v) tax considerations.

Altria determined that selling its investment in ABI at this time would not maximize long-term shareholder value; therefore, Altria currently plans to maintain its ABI investment. Altria continues to have confidence in ABI’s (i) long-term strategies; (ii) premium global brands; (iii) experienced management team; and (iv) capability to successfully navigate near-term challenges.

Altria will continue to monitor and evaluate market conditions and the analytical factors described above on a regular basis, in accordance with its goal of maximizing the long-term shareholder value of this investment.

Environmental, Social and Governance (ESG)

Altria’s Corporate Responsibility Focus Areas are (i) reducing the harm of tobacco products, (ii) preventing underage use, (iii) protecting the environment, (iv) driving responsibility through our value chain, (v) supporting our people and communities and (vi) engaging and leading responsibly. Altria’s corporate responsibility reports can be found on the Corporate Responsibility Reports page at www.altria.com/responsibility.

  • In October, Altria released its 2020-2021 Reducing Harm and Preventing Underage Use corporate responsibility report.

  • In support of its underage use prevention efforts, Altria announced its sponsorship of TruAge™, a digital age-verification system. Built for any store or brand that sells age-restricted products, TruAge™ verifies a customer’s age at all points of sale while keeping personal information private. Altria expects a pilot to be initiated by year-end.

  • In the third quarter, Altria was recognized as a Great Place to Work Certified™ company and was ranked as a Best Workplace for Millennials and in Manufacturing and Production by Fortune magazine and Great Place to Work®. Altria was also recognized as one of the best places to work in IT by IDG Insider Pro and ComputerWorld.

  • In support of its Talent and Culture initiative, Altria Group Distribution Company launched The Stronger Together Challenge, an industry program to fund proposals that amplify inclusion, diversity and equity efforts in the convenience store industry.

  • In November, Altria expects to issue its 2020-2021 Protect the Environment corporate responsibility report.

Impact of COVID-19 Pandemic

Impact on Tobacco Business Operations

  • Altria’s tobacco businesses have not experienced a material adverse impact to date due to the COVID-19 pandemic, but there is continued uncertainty as to how the COVID-19 pandemic (including changes in COVID-19-related restrictions and guidelines) may impact adult tobacco consumers (ATC) in the future. Altria continues to monitor the macroeconomic risks of the COVID-19 pandemic (including risks associated with the timing and extent of vaccine administration and the impact of COVID-19 variants), and their effect on ATC, including stay-at-home practices and disposable income, which may be further impacted by unemployment rates and inflation. Altria also continues to monitor ATC purchasing behaviors, including overall tobacco product expenditures, mix between premium and discount brand purchases and adoption of smoke-free products.

  • Altria believes that the COVID-19 pandemic altered ATC behaviors and purchasing patterns, particularly in the earlier stages of the pandemic. While the number of ATC trips to the store remain below pre-pandemic levels and tobacco expenditures per trip remain elevated, the environment continues to evolve as the effects of government stimulus have lessened and consumer mobility returns to more normal levels.

  • Altria’s suppliers and those within its distribution chain continue to be subject to potential facility closures, remote working protocols, and labor shortages. To date, Altria has not experienced any material disruptions to its supply chains or distribution systems but is continuing to monitor these factors. Altria continues to monitor the risk that the business of one or more suppliers, distributors or any other entities within its supply and distribution chains may be disrupted.

Impact on JUUL and Cronos Investments

  • During 2020 and the first nine months of 2021, JUUL’s operations were negatively impacted by the COVID-19 pandemic due to stay-at-home practices and government-mandated restrictions. While the impact was considered in Altria’s quantitative valuations conducted in connection with the preparation of its financial statements for the nine months ended September 30, 2021 and during 2020, Altria does not believe the COVID-19 pandemic was a primary driver of the non-cash, pre-tax impairment charge recorded during 2020 or any quarterly changes in fair value recorded since the fourth quarter of 2020. Altria will continue to monitor the impact of the COVID-19 pandemic on JUUL’s business, including near-term supply chain constraints and component part shortages.

  • During 2020 and the first nine months of 2021, Cronos has been adversely impacted by the COVID-19 pandemic, due in part to government actions limiting access to retail stores in the United States and Canada, including the recording in 2020 of an impairment charge on certain goodwill and intangible assets. However, the continued rollout of vaccines in the United States and Canada has resulted in the easing of COVID-19 related restrictions in most of the United States and Canada during the third quarter of 2021. Altria will continue to monitor the impact of COVID-19 pandemic on Cronos’ business, including near-term supply chain challenges, and market valuation.

2021 Full-Year Guidance

Altria narrows its guidance for 2021 full-year adjusted diluted EPS to be in a range of $4.58 to $4.62, representing a growth rate of 5% to 6% from an adjusted diluted EPS base of $4.36 in 2020. While the 2021 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic. Altria will continue to monitor conditions related to (i) the economy (including unemployment rates and the impact of increased inflation), (ii) ATC dynamics, including stay-at-home practices, disposable income, purchasing patterns and adoption of smoke-free products, (iii) regulatory and legislative (including excise tax) developments and (iv) the timing and extent of COVID-19 vaccine administration and the impact of COVID-19 variants.

Altria’s 2021 full-year adjusted diluted EPS guidance range includes planned investments in support of its Vision, such as (i) marketplace investments to expand the availability and awareness of Altria’s smoke-free products, (ii) costs associated with building an industry-leading consumer engagement platform that enhances data collection and insights in support of ATC transition to smoke-free products and (iii) increased smoke-free product research and development expense. The full-year adjusted diluted EPS guidance range excludes the special items for the first nine months of 2021 shown in Table 1.

Altria continues to expect its 2021 full-year adjusted effective tax rate will be in a range of 24.5% to 25.5%.

Altria expects its 2021 capital expenditures to be between $150 million and $200 million, a change from its previous expectation of $200 million to $250 million.

Altria’s full-year adjusted diluted EPS guidance and full-year forecast for its adjusted effective tax rate exclude the impact of certain income and expense items that management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition-related and disposition-related costs, COVID-19 special items, equity investment-related special items (including any changes in fair value of the equity investment and any related warrants and preemptive rights), certain tax items, charges associated with tobacco and health and certain other litigation items, and resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the 1998 Master Settlement Agreement (such dispute resolutions are referred to as NPM Adjustment Items).

Altria’s management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on its reported diluted EPS or its reported effective tax rate because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, Altria does not provide a corresponding U.S. generally accepted accounting principles (GAAP) measure for, or reconciliation to, its adjusted diluted EPS guidance or its adjusted effective tax rate forecast.

ALTRIA GROUP, INC.

See "Basis of Presentation" below for an explanation of financial measures and reporting segments discussed in this release.

Financial Performance

Third Quarter

  • Net revenues decreased 4.7% to $6.8 billion, primarily driven by lower net revenues in the smokeable products segment. Revenues net of excise taxes decreased 2.6% to $5.5 billion.

  • Reported diluted EPS decreased (+100.0)% to ($1.48), primarily driven by lower reported earnings from Altria’s investment in ABI (due primarily to 2021 impairment of its investment in ABI) and lower reported operating companies income (OCI). These items were partially offset by the 2020 impairment of JUUL equity securities, an increase in the estimated fair value of Altria’s investment in JUUL, favorable Cronos-related special items, favorable net periodic benefit income, lower interest expense and fewer shares outstanding.

  • Adjusted diluted EPS increased 2.5% to $1.22, primarily driven by higher adjusted earnings from Altria’s equity investment in ABI, favorable net periodic benefit income, lower adjusted income tax rate, lower interest expense and fewer shares outstanding, partially offset by lower adjusted OCI.

First Nine Months

  • Net revenues decreased 0.5% to $19.8 billion, primarily driven by lower net revenues in the smokeable products segment, partially offset by higher net revenues in the wine segment, oral tobacco segment and the financial services business. Revenues net of excise taxes increased 1.5% to $16.0 billion.

  • Reported diluted EPS decreased 66.2% to $0.46, primarily driven by lower reported earnings from Altria’s investment in ABI (due primarily to 2021 impairment of its investment in ABI), losses on early extinguishment of debt and unfavorable Cronos-related special items. These items were partially offset by the 2020 impairment of JUUL equity securities, higher reported OCI, favorable periodic net benefit income and fewer shares outstanding.

  • Adjusted diluted EPS increased 4.5% to $3.52, primarily driven by higher adjusted OCI in the smokeable products segment, favorable net periodic benefit income, higher adjusted earnings from Altria’s investment in ABI and fewer shares outstanding, partially offset by a higher adjusted income tax rate.

Table 1 - Altria’s Adjusted Results

Third Quarter

Nine Months Ended September 30,

2021

2020

Change

2021

2020

Change

Reported diluted EPS

$

(1.48)

$

(0.51)

(100)%+

$

0.46

$

1.36

(66.2) %

NPM Adjustment Items

(0.02)

(0.03)

Implementation, acquisition and disposition-

related costs

0.03

0.05

0.17

Tobacco and health and certain other litigation items

0.04

0.01

0.06

0.03

Impairment of JUUL equity securities

1.40

1.40

JUUL changes in fair value

(0.05)

ABI-related special items

2.65

0.22

2.60

0.29

Cronos-related special items

0.05

0.08

0.11

0.08

Loss on early extinguishment of debt

0.27

COVID-19 special items

0.02

Tax items

(0.01)

0.02

Adjusted diluted EPS

$

1.22

$

1.19

2.5

%

$

3.52

$

3.37

4.5

%

Note: For details of pre-tax, tax and after-tax amounts, see Schedules 7 and 9.

Special Items

The EPS impact of the following special items is shown in Table 1 and Schedules 6, 7, 8 and 9.

Non-Participating Manufacturer (NPM) Adjustment Items

  • In the third quarter and first nine months of 2021, Altria recorded pre-tax income of $44 million (or $0.02 per share) and $76 million (or $0.03 per share), respectively, due to NPM Adjustment Items and related interest. For the third quarter and first nine months, Altria recorded $21 and $53 million, respectively, as a reduction to cost of sales in the smokeable products segment, and recorded $23 million as interest income in both periods.

Implementation, acquisition and disposition-related costs

  • In the third quarter of 2021, Altria recorded pre-tax charges of $61 million (or $0.03 per share), due primarily to charges associated with the sale of the Ste. Michelle wine business.

  • In the first nine months of 2021, Altria recorded pre-tax charges of $117 million (or $0.05 per share), due primarily to charges associated with the sale of the Ste. Michelle wine business and acquisition-related costs for the settlement of an arbitration related to the 2019 on! transaction.

  • In the first nine months of 2020, Altria recorded pre-tax charges of $415 million (or $0.17 per share), due primarily to inventory-related charges recorded by Ste. Michelle consisting of $292 million for a wine inventory write-off and $100 million for estimated losses on future, non-cancelable grape purchase commitments (both recorded in the first quarter of 2020) that Ste. Michelle believed no longer had a future economic benefit.

Tobacco and Health and Certain Other Litigation Items

  • In the third quarter and first nine months of 2021, Altria recorded pre-tax charges of $105 million (or $0.04 per share) and $148 million (or $0.06 per share), respectively, for tobacco and health and certain other litigation items and interest costs.

  • In the first nine months of 2020, Altria recorded pre-tax charges of $76 million (or $0.03 per share) for tobacco and health litigation items and interest costs.

Impairment of JUUL Equity Securities

  • In the third quarter and first nine months of 2020, Altria recorded a non-cash pre-tax impairment charge of $2.6 billion ($1.40 per share) due to the impairment of Altria’s equity securities in JUUL. A full tax valuation allowance was recorded for this charge that offset the tax benefit associated with the impairment charge.

JUUL Changes in Fair Value

  • In the third quarter of 2021, Altria recorded a non-cash pre-tax unrealized gain of $100 million (or $0.05 per share) as a result of an increase in the estimated fair value of its investment in JUUL. A corresponding adjustment was made to the JUUL tax valuation allowance.

  • As of September 30, 2021, the estimated fair value of Altria’s JUUL investment was $1.7 billion, unchanged from its December 31, 2020 estimated fair value.

ABI-Related Special Items

  • In the third quarter and first nine months of 2021, equity earnings from ABI included net pre-tax charges of $6.2 billion ($2.65) and $6.1 billion ($2.60), respectively, substantially all of which related to an impairment of Altria’s investment in ABI.

  • In the third quarter of 2020, losses from Altria’s investment in ABI included net pre-tax charges of $513 million (or $0.22 per share), consisting primarily of ABI’s completion of the sale of its Australia subsidiary and ABI’s goodwill impairment charge associated with its Africa businesses.

  • In the first nine months of 2020, losses from Altria’s investment in ABI included net pre-tax charges of $689 million (or $0.29 per share), consisting primarily of ABI’s (i) mark-to-market losses on certain ABI financial instruments associated with its share commitments, (ii) completion of the sale of its Australia subsidiary and (iii) goodwill impairment charge associated with its Africa businesses.

The ABI-related special items above include Altria’s respective share of the amounts recorded by ABI and may also include additional adjustments related to (i) conversion from international financial reporting standards to GAAP and (ii) adjustments to Altria’s investment required under the equity method of accounting.

Cronos-Related Special Items

In the third quarter and first nine months of 2021, Altria recorded net pre-tax (income) expense consisting of the following:

Third Quarter

Nine Months Ended September 30,

($ in millions, except per share data)

2021

2020

2021

2020

(Gain) loss on Cronos-related financial

instruments 1

$

135

$

105

$

128

$

202

(Income) losses from equity investments 2

(46)

38

72

(58)

Total Cronos-related special items - (income)

expense

$

89

$

143

$

200

$

144

Earnings per share

$

0.05

$

0.08

$

0.11

$

0.08

1 Amounts are related to the non-cash change in the fair value of the warrant and certain anti-dilution protections acquired in the Cronos transaction.

2 Amounts include Altria’s share of special items recorded by Cronos and may also include adjustments to Altria’s investment required under the equity method of accounting.

Loss on Early Extinguishment of Debt

  • In the first nine months of 2021, Altria recorded pre-tax losses on early extinguishment of debt of $649 million (or $0.27 per share), which was recorded in the first quarter.

COVID-19 Special Items

  • In the first nine months of 2020, Altria recorded net pre-tax charges of $50 million (or $0.02 per share), directly related to disruptions caused by or efforts to mitigate the impact of the COVID-19 pandemic. These net pre-tax charges included premium pay, personal protective equipment and health screenings, partially offset by certain employment tax credits. The COVID-19 special items do not include the inventory-related implementation costs associated with the 2020 wine business strategic reset.

Tax Items

  • In the first nine months of 2020, Altria recorded net income tax expense of $38 million (or $0.02 per share), primarily related to a tax basis adjustment to Altria’s investment in ABI and adjustments as a result of amended returns and audit adjustments related to prior years.

SMOKEABLE PRODUCTS

Revenues and OCI

Third Quarter

  • Net revenues decreased 5.4%, primarily driven by lower shipment volume, partially offset by higher pricing and lower promotional investments. Revenues net of excise taxes decreased 3.0%.

  • Reported OCI decreased 1.3%, primarily driven by lower shipment volume and higher resolution expense, partially offset by higher pricing, lower promotional investments and 2021 NPM Adjustment Items.

  • Adjusted OCI decreased 2.2%, primarily driven by lower shipment volume and higher resolution expense, partially offset by higher pricing and lower promotional investments. Adjusted OCI margins increased by 0.5 percentage points to 58.0%.

First Nine Months

  • Net revenues decreased 1.4%, primarily driven by lower shipment volume, partially offset by higher pricing. Revenues net of excise taxes increased 0.6%.

  • Reported OCI increased 3.8%, primarily driven by higher pricing, 2021 NPM Adjustment Items and 2020 COVID-19 special items, partially offset by lower shipment volume, higher resolution expenses and higher costs.

  • Adjusted OCI increased 2.6%, primarily driven by higher pricing, partially offset by lower shipment volume, higher resolution expenses and higher costs. Adjusted OCI margins increased by 1.1 percentage points to 58.0%.

Table 2 - Smokeable Products: Revenues and OCI ($ in millions)

Third Quarter

Nine Months Ended September 30,

2021

2020

Change

2021

2020

Change

Net revenues

$

5,975

$

6,313

(5.4)%

$

17,275

$

17,522

(1.4)%

Excise taxes

(1,218)

(1,407)

(3,620)

(3,950)

Revenues net of excise taxes

$

4,757

$

4,906

(3.0)%

$

13,655

$

13,572

0.6%

Reported OCI

$

2,753

$

2,789

(1.3)%

$

7,901

$

7,609

3.8%

NPM Adjustment Items

(21)

(53)

Tobacco and health and certain other litigation items

29

34

72

73

COVID-19 special items

41

Adjusted OCI

$

2,761

$

2,823

(2.2)%

$

7,920

$

7,723

2.6%

Adjusted OCI margins 1

58.0

%

57.5

%

0.5 pp

58.0

%

56.9

%

1.1 pp

1 Adjusted OCI margins are calculated as adjusted OCI divided by revenues net of excise taxes.

Shipment Volume

Third Quarter

  • Smokeable products segment reported domestic cigarette shipment volume decreased 12.9%, primarily driven by the industry’s rate of decline and trade inventory movements.

  • When adjusted for trade inventory movements, smokeable products segment domestic cigarette shipment volume decreased by an estimated 7.0%.

  • When adjusted for trade inventory movements and other factors, total estimated domestic cigarette industry volume decreased by an estimated 6.5%.

  • Reported cigar shipment volume decreased 9.8%.

First Nine Months

  • Smokeable products segment reported domestic cigarette shipment volume decreased 8.0%, primarily driven by the industry’s rate of decline, trade inventory movements, calendar differences and other factors.

  • When adjusted for trade inventory movements, calendar differences and other factors, smokeable products segment domestic cigarette shipment volume decreased by an estimated 5.0%.

  • When adjusted for trade inventory movements, calendar differences and other factors, total estimated domestic cigarette industry volume decreased by an estimated 5.0%.

  • Reported cigar shipment volume increased 2.7%.

Table 3 - Smokeable Products: Shipment Volume (sticks in millions)

Third Quarter

Nine Months Ended September 30,

2021

2020

Change

2021

2020

Change

Cigarettes:

Marlboro

21,368

24,258

(11.9)

%

63,122

67,890

(7.0)

%

Other premium

1,042

1,231

(15.4)

%

3,180

3,496

(9.0)

%

Discount

1,640

2,130

(23.0)

%

5,068

6,205

(18.3)

%

Total cigarettes

24,050

27,619

(12.9)

%

71,370

77,591

(8.0)

%

Cigars:

Black & Mild

424

468

(9.4)

%

1,356

1,317

3.0

%

Other

1

3

(66.7)

%

5

8

(37.5)

%

Total cigars

425

471

(9.8)

%

1,361

1,325

2.7

%

Total smokeable products

24,475

28,090

(12.9)

%

72,731

78,916

(7.8)

%

Note: Cigarettes volume includes units sold as well as promotional units, but excludes units sold for distribution to Puerto Rico, and units sold in U.S. Territories, to overseas military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to the smokeable products segment.

Retail Share and Brand Activity

Third Quarter

  • Marlboro retail share of the total cigarette category was unchanged at 43.2%.

  • The industry retail share for the discount cigarette segment increased 0.6 share points to 25.3%.

First Nine Months

  • Marlboro retail share of the total cigarette category increased 0.4 share points to 43.2%.

  • The industry retail share for the discount cigarette segment increased 0.3 share points to 25.2%.

Table 4 - Smokeable Products: Cigarettes Retail Share (percent)

Third Quarter

Nine Months Ended September 30,

2021

2020

Percentage
point change

2021

2020

Percentage
point change

Cigarettes:

Marlboro

43.2

%

43.2

%

43.2

%

42.8

%

0.4

Other premium

2.3

2.3

2.3

2.3

Discount

3.4

3.8

(0.4)

3.5

4.0

(0.5)

Total cigarettes

48.9

%

49.3

%

(0.4)

49.0

%

49.1

%

(0.1)

Note: Retail share results for cigarettes are based on data from IRI/MSAi, a tracking service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers (STARS). This service is not designed to capture sales through other channels, including the internet, direct mail and some illicitly tax-advantaged outlets. It is IRI’s standard practice to periodically refresh its services, which could restate retail share results that were previously released in this service.

ORAL TOBACCO PRODUCTS

Revenues and OCI

Third Quarter

  • Net revenues decreased 2.2%, primarily driven by lower shipment volume (including changes in shipment volume mix between the segment’s moist smokeless tobacco (MST) and oral nicotine pouch products), and higher promotional investments in on!, partially offset by higher pricing. Revenues net of excise taxes decreased 2.1%.

  • Reported and adjusted OCI decreased 7.1% and 8.0%, respectively, primarily driven by lower shipment volume (including unfavorable shipment volume mix), higher promotional investments in on! and higher costs, partially offset by higher pricing. Adjusted OCI margins declined by 4.3 percentage points to 68.2%, due to changes in shipment volume mix between the segment’s MST and oral nicotine pouch products.

First Nine Months

  • Net revenues increased 2.3%, primarily driven by higher pricing, partially offset by higher promotional investments in on! and lower shipment volume (including unfavorable shipment volume mix). Revenues net of excise taxes increased 2.4%.

  • Reported OCI decreased 2.2% primarily driven by higher promotional investments in on!, higher costs (including acquisition-related costs) and lower shipment volume (including unfavorable shipment volume mix), partially offset by higher pricing.

  • Adjusted OCI was essentially unchanged, as higher promotional investments in on!, lower shipment volume (including unfavorable shipment volume mix) and higher costs were mostly offset by higher pricing. Adjusted OCI margins declined by 2.1 percentage points to 70.7%, due to changes in shipment volume mix between the segment’s MST and oral nicotine pouch products.

Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)

Third Quarter

Nine Months Ended September 30,

2021

2020

Change

2021

2020

Change

Net revenues

$

626

$

640

(2.2)

%

$

1,945

$

1,901

2.3

%

Excise taxes

(32)

(33)

(98)

(98)

Revenues net of excise taxes

$

594

$

607

(2.1)

%

$

1,847

$

1,803

2.4

%

Reported OCI

$

405

$

436

(7.1)

%

$

1,269

$

1,297

(2.2)

%

Acquisition-related costs

4

37

6

COVID-19 special items

9

Adjusted OCI

$

405

$

440

(8.0)

%

$

1,306

$

1,312

(0.5)

%

Adjusted OCI margins 1

68.2

%

72.5

%

(4.3) pp

70.7

%

72.8

%

(2.1) pp

1 Adjusted OCI margins are calculated as adjusted OCI divided by revenues net of excise taxes.

Shipment Volume

Third Quarter

  • Oral tobacco products segment reported domestic shipment volume decreased 3.8%, primarily driven by retail share losses (primarily due to the growth of oral nicotine pouches) and trade inventory movements, partially offset by industry growth, calendar differences and other factors. When adjusted for trade inventory movements and calendar differences, oral tobacco products segment shipment volume decreased by an estimated 2.5%.

First Nine Months

  • Oral tobacco products segment reported domestic shipment volume decreased 0.5%, primarily driven by retail share losses (primarily due to the growth of oral nicotine pouches) and calendar differences, partially offset by industry growth and trade inventory movements. When adjusted for trade inventory movements and calendar differences, oral tobacco products segment shipment volume decreased by an estimated 0.5%.

  • Total oral tobacco industry volume increased by an estimated 3% over the past six months, driven by growth in oral nicotine pouches.

Table 6 - Oral Tobacco Products: Shipment Volume (cans and packs in millions)

Third Quarter

Nine Months Ended September 30,

2021

2020

Change

2021

2020

Change

Copenhagen

121.4

131.1

(7.4)

%

395.0

(4.2)

%

Skoal

47.7

52.3

(8.8)

%

148.2

157.2

(5.7)

%

Other (includes Red Seal and on!)

29.7

23.3

27.5

%